|  |  |  |  |
| --- | --- | --- | --- |
| Порядковый номер ссылки | Авторы, название публикации, источника, выходные данные | Ф.И.О. , название публикации на английском языке | Полный интернет адрес (URL) цитируемой статьи, doi |
| 1 | Виксман М. Е., Маянский А.Н. Способ оценки функциональной активности нейтрофилов человека по реакции восстановления нитросинего тетразолия : метод. рек. – Казань, 1979. – 14 с. | Viksman M. E., Mayanskij A.N. A method of estimating functional activity of human neutrophils by the reaction of nitro blue tetrazolium recovery: method. rivers. Kazan', 1979, 14 р. | - |
| 2 | Гайдарова А. П., Корощенко Г. А., Айзман Р. И. Влияние куркумы и куркумина на углеводный обмен при аллоксан-индуцированном сахарном диабете у крыс// Современные проблемы науки и образования. – 2014. – №.5. – С.597.  | Gaidarova A. P., Koroshchenko G. A., Aizman R. I. Effect of turmeric and curcumin on carbohydrate metabolism in alloxan-induced diabetes mellitus in rats. Modern problems of science and education. 2014, no. 5, p. 597. |  http://science-education.ru/ru/article/view?id=14779 (дата обращения: 25.09.2019). |
| 3 | Гончарик И.И. Болезнь Крона // Военная медицина. - 2013. - № 4. - C.113-117. | Goncharik I.I . Crohn's diseas. Military medicine, 2013, no. 4, pp. 113-117. | https://www.bsmu.by/militarymedicine/390a7cf979251cfbd1b144edfdaa38d8/. |
| 4 | Долгушин, И. И., Бухарин О.В. Нейтрофилы и гомеостаз. – Екатеринбург : Институт клеточ. и внутриклеточ. симбиоза УрО РАН, 2001. – 277 с. | Dolgushin, I. I., Buharin O.V. Neutrophils and homeostasis. Ekaterinburg : Institut kletoch. i vnutrikletoch. simbioza UrO RAN, 2001, 277 р.  | - |
| 5 | Емельянова В.А., Демидов А.А. Воспалительные заболевания кишечника и ревматоидный артрит: современные вопросы патогенеза // Современные проблемы науки и образования [Электронный ресурс]. 2015. № 6. (Дата обращения: 26.09.2019) | Emel'yanova V.A., Demidov A.A. Inflammatory bowel diseases and rheumatoid arthritis: current issues of pathogenesis. Modern problems of science and education [An electronic resource], 2015, no. 6 (date of address 26.09.2019). | <http://www.science-education.ru/ru/article/view?id=23850> (дата обращения: 26.09.2019) |
| 6 | Павленко В.В., Катаганова Г.А. Некоторые механизмы регуляции апоптоза при болезни Крона // Медицинский вестник Северного Кавказа. – 2011. - № 4. – С. 66 – 68. | Pavlenko V.V., Kataganova G.A. Some mechanisms of apoptosis regulation in Crohn's disease. Medical Bulletin of the North Caucasus, 2011, no. 4, pp. 66-68.  | https://cyberleninka.ru/article/n/nekotorye-mehanizmy-regulyatsii-apoptoza-pri-bolezni-krona |
| 7 | Фрейдлин. И. С. Методы изучения фагоцитирующих клеток при оценке иммунного статуса человека : учебное пособие. - Ленинград, 1986. – 37 с. | Frejdlin. I. S. Methods of studying phagocytic cells in assessing the immune status of a person: tutorial. Leningrad, 1986, 37р. | - |
| 8 | Aggeletopoulou I., Assimakopoulos S.F., Konstantakis C., Triantos C. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease. World J Gastroenterol, 2018, Vol. 24, no. 36, pp. 4093-4103. |  | <https://www.ncbi.nlm.nih.gov/pubmed/30271076>[doi: 10.3748/wjg.v24.i36.4093.] |
| 9 | Anthwal A., Thakur B. K., Rawat M. S.M., Rawat D. S., Tyagi A.K., Aggarwal B.B. S ynthesis, characterization and in vitro anticancer activity of C-5 curcumin analogues with potential to inhibit TNF-alpha-induced NF-kappaB activation. BioMed Res. Int, 2014, Vol. 2014, doi: 10.1155/2014/524161 |  | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135142/> [doi: 10.1155/2014/524161] |
| 10  | Burge K., Gunasekaran A., Eckert J., Chaaban H. Curcumin and Intestinal Inflammatory Diseases: Molecular Mechanisms of Protection. Int J Mol Sci, 2019, Vol. 20, no. 8, p.1912. |  | <https://www.ncbi.nlm.nih.gov/pubmed/31003422>[doi:10.3390/ijms20081912] |
| 11  | Cooper H.S., Murthy S.N., Shah R.S., Sedergran, D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest, 1993, Vol. 69, no. 2, pp. 238-249. |  | https://www.ncbi.nlm.nih.gov/pubmed/8350599 |
| 12 | Curkovic I., Egbring M., Kullak-Ublick G. Risks of Inflammatory Bowel Disease Treatment with Glucocorticosteroids and Aminosalicylates. Dig Dis, 2013, no.3, pp. 368-373. |  | <https://www.ncbi.nlm.nih.gov/pubmed/24246990> [doi: 10.1159/000354699] |
| 13 | Gao X., Kuo J., Jiang H., Deeb D., Liu Y., Divine G., Chapman R.A., Dulchavsky S.A., Gautam S.C. Immunomodulatory activity of curcumin: Suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro. Biochem. Pharm,acol, 2004, no. 68, pp. 51–61. |  | <https://www.ncbi.nlm.nih.gov/pubmed/15183117>[10.1016/j.bcp.2004.03.015] |
| 14 | Geremia A., Arancibia-Cárcamo C.V., Fleming M.P., Rust N., Singh B., Mortensen N.J., Travis S.P., Powrie F. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med, 2011 Vol. 208, no. 6, pp. 1127-1133. |  | <https://www.ncbi.nlm.nih.gov/pubmed/21576383>[doi: 10.1084/jem.20101712] |
| 15 | Gupta S.C., Patchva S., Aggarwal B.B. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J, 2013, no. 15, pp. 195-218.  |  | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535097/>[doi:10.1208/s12248-012-9432-8] |
| 16 | Gupta S. C., Tyagi A. K., Deshmukh-Taskar P. Hinojosa M., Prasad S., Aggarwal B.B. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Arch Biochem Biophys, 2014, Vol. 559, pp. 91–99. |  | <https://www.ncbi.nlm.nih.gov/pubmed/24946050>[doi: 10.1016/j.abb.2014.06.0] |
| 17 | Longman R.S., Diehl G.E., Victorio D.A., Huh J.R., Galan C., Miraldi E.R, Swaminath A., Bonneau R., Scherl E.J., Littman D.R. CX3CR1+ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. J Exp Med, 2014, no. 211, рр. 1571–1583. |  | <https://www.ncbi.nlm.nih.gov/pubmed/25024136>[doi: 10.1084/jem.20140678] |
| 18 | Magro F., Rodrigues-Pinto E., Coelho R., Andrade P., Santos-Antunes J., Lopes S., Camila-Dias C., Macedo G. Is it possible to change phenotype progression in Crohn’s disease in the era of immunomodulators? Predictive factors of phenotype progression. Am J Gastroenterol, 2014, Vol.109, no. 7, pp.1026-36. |  | <https://www.ncbi.nlm.nih.gov/pubmed/24796767>[doi: 10.1038/ajg.2014.97] |
| 19 | Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, 1989, Vol. 96, no.3, pp. 795–803. |  | <https://www.ncbi.nlm.nih.gov/pubmed/2914642> |
| 20 | Muthupalani S., Ge Z., Feng Y., Rickman B., Mobley M., McCabe A., Van Rooijen N., Fox J.G. Systemic macrophage depletion inhibits Helicobacter bilis-induced proinflammatory cytokine-mediated typhlocolitis and impairs bacterial colonization dynamics in a BALB/c Rag2−/− mouse model of inflammatory bowel disease. Infect Immun, 2012, Vol. 80, no.12, pp. 4388–4397. |  | <https://www.ncbi.nlm.nih.gov/pubmed/23027534>[doi: 10.1128/IAI.00530-12] |
| 21 | Ness-Schwickerath K.J., Jin C., Morita C.T. Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells. J Immunol, 2010, Vol. 184, no. 12, pp. 7268-7080. |  | <https://www.ncbi.nlm.nih.gov/pubmed/20483730>[doi: 10.4049/jimmunol.1000600] |
| 22 | Neurath M.F. IL-23 in inflammatory bowel diseases and colon cancer. Cytokine Growth Factor Rev. 2019, no. 45, pp. 1-8. |  | <https://www.ncbi.nlm.nih.gov/pubmed/30563755>[doi: 10.1016/j.cytogfr.2018.12.00] |
| 23 | Neurath M.F., Leppkes M. Resolution of ulcerative colitis. Semin Immunopathol, 2019, doi: 10.1007/s00281-019-00751-6 |  | <https://www.ncbi.nlm.nih.gov/pubmed/31278430>[doi: 10.1007/s00281-019-00751-6] |
| 24 | Omenetti S., Pizarro T.T. The Treg/Th17 Axis: A Dynamic Balance Regulated by the Gut Microbiome Front Immunol. 2015, no. 6, pp. 639. |  | <https://www.ncbi.nlm.nih.gov/pubmed/2673400>[doi: 10.3389/fimmu.2015.00639] |
| 25 | Sales-Campos H., Basso P.J., Alves V.B., Fonseca M.T., Bonfá G., Nardini V., Cardoso C.R. Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med and Biol Res, 2014, Vol. 48, no. 2, pp. 96-107/ |  | <https://www.ncbi.nlm.nih.gov/pubmed/25425466>[doi: 10.1590/1414-431X20143774] |
| 26 | Sedda S., Bevivino G., Monteleone G. Targeting IL-23 in Crohn's disease. Expert Rev Clin Immunol, 2018, Vol. 14, no. 11, pp. 907-913. |  | <https://www.ncbi.nlm.nih.gov/pubmed/30223688>[doi: 10.1080/1744666X.2018.1524754] |
| 27 | Shaw M.H., Kamada N., Kim Y.G., Núñez G. Microbiota-induced IL-1β, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J Exp Med. 2012, Vol. 209, no. 2, pp. 251- 259. |  | <https://www.ncbi.nlm.nih.gov/pubmed/22291094>[doi: 10.1084/jem.20111703] |
| 28 | Tian T., Wang Z., Zhang J. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. Oxid med cell longev, Vol. 2017, Article ID: 4535194 (18 pages): doi: 10.1155/2017/4535194 |  | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506473/>[doi: 10.1155/2017/4535194] |